» Download Public Reports
About 600 reports
- Country report
- March 2013
- 110 pages
... Vaccine preventable diseases requirements of the infectious diseases programs standard. In addition, the report supports ongoing education for board of health members to help them remain abreast ...
March 2013
... With mental illness or concurrent disorders. Throughout 2012, the working group met regularly to help guide the work of this project and act as champions in the sector. The organizations represented ...
March 2013
... Of investments necessary to increase the supply of supportive housing for people living with mental illness. The discussion paper and the tool kit suggest that social financing can play a role in the development ...
March 2013
... From 354-square-foot studio apartments for those with mental illness, to 1,608- square-foot, four-bedroom apartments for people with brain injuries. After years of design, fundraising and political ...
March 2013
... Say these treatments should be available to all people with depression or anxiety disorders or schizophrenia, unless the problem is very mild or recent. The report concluded that treatments according ...
March 2013
... Available for the early detection of heart attack, congestive heart failure, flu a + b and rsv. In the non-clinical market, ramp tests are currently available for the environmental detection of west nile ...
April 2013
... Formulated diclofenac by thermis. Top international stories positive data from vertex S cystic fibrosis drug:- boston-based vertex pharmaceuticals has reported positive data from a phase-2 clinical trial ...
April 2013
... breast cancer. It is reported that up to 30% of her2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier ...
April 2013
... Med 2006;38:52-63 these features lead to type 2 diabetes and cardiovascular disease visceral obesity is associated with a cluster of metabolic abnormalities often described as the Metabolic syndrome ...
April 2013
... Outcomes Risk time Outcome smoking Cancer, cvd, stroke overweight/obesity Cvd, stroke, diabetes, cancer, mental illness alcohol abuse Cvd, cancer, mental illness, injury where does information ...
» Purchase Premium Reports
(From $ 125 - $ 4 995)
About 200 reports
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and ...
March 2013
$ 3 495
Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Copaxone (Multiple Sclerosis) - Forecast and Market ...
March 2013
$ 3 495
Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Betaseron/Betaferon (Multiple Sclerosis) ...
March 2013
$ 3 495
Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Avonex (Multiple Sclerosis) - Forecast and Market Analysis ...
March 2013
$ 3 495
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Gilenya (Multiple Sclerosis) - Forecast and Market Analysis ...
March 2013
$ 3 495
Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Tysabri (Multiple Sclerosis) - Forecast and Market Analysis ...
March 2013
$ 3 495
Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Rebif (Multiple Sclerosis) - Forecast and Market Analysis ...
